We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Lenalidomide and Paclitaxel in Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00933426
Recruitment Status : Terminated (Terminated early due to slow accrual as Phase I dose escalation study.)
First Posted : July 7, 2009
Last Update Posted : October 26, 2016
Celgene Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Primary Completion Date : December 2015
  Study Completion Date : December 2015